Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02)

被引：0

作者：

Oh, Do-Youn

Lugowska, Iwona A.

Stroyakovskiy, Daniil

Jung, Kyung Hae

Dumas, Olivier

Penkov, Konstantin

Dechaphunkul, Arunee

Oaknin, Ana

Kim, Seung Tae

Starling, Naureen

Chewaskulyong, Busyamas

Charonpongsuntorn, Chanchai

Doroshow, Deborah Blythe

Hsiao, Sheng-Yen

Hung, Yi-Ping

Jung, Lindsey

Kuptsova-Clarkson, Nataliya

Michelini, Flavia

Puvvada, Soham D.

Meric-Bernstam, Funda

机构：

[1] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[2] Maria Sklodowska Curie Natl Res Inst & Oncol Ctr, Early Phase Clin Trials Dept, Warsaw, Poland

[3] Moscow City Oncol Hosp 62, Moscow, Russia

[4] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea

[5] Hotel Dieu Quebec, Quebec City, PQ, Canada

[6] Clin Hosp RZHD Med, St Petersburg, Russia

[7] Prince Songkla Univ, Dept Med, Med Oncol Unit, Fac Med, Hat Yai, Thailand

[8] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol, Gynaecol Canc Programme, Barcelona, Spain

[9] Samsung Med Ctr, Seoul, South Korea

[10] Royal Marsden NHS Fdn Trust, Gastrointestinal Unit, London, England

[11] Inst Canc Res, London, England

[12] Chiang Mai Univ, Chiang Mai, Thailand

[13] Srinakharinwirot Univ, Dept Internal Med, Med Oncol Unit, Fac Med, Nakhon Nayok, Thailand

[14] Icahn Sch Med Mt Sinai, New York, NY USA

[15] Chi Mei Med Ctr, Div Hematol Oncol, Dept Internal Med, Tainan, Taiwan

[16] Taipei Vet Gen Hosp, Taipei, Taiwan

[17] AstraZeneca, Gaithersburg, MD USA

[18] AstraZeneca, Oncol R&D, Gaithersburg, MD USA

[19] AstraZeneca, Translat Med, Oncol R&D, Waltham, MA USA

[20] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4090

引用

页数：1

共 50 条

[31] Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC)
Siena, S.
Raghav, K.
Masuishi, T.
Yamaguchi, K.
Nishina, T.
Elez, E.
Rodriguez, J.
Chau, I.
Di Bartolomeo, M.
Kawakami, H.
Suto, F.
Kobayashi, K.
Koga, M.
Inaki, K.
Kuwahara, Y.
Takehara, I.
Grothey, A.
Yoshino, T.
ANNALS OF ONCOLOGY, 2021, 32 : S532 - S532
[32] A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01
Yoshino, T.
Siena, S.
Di Bartolomeo, M.
Raghav, K.
Masuishi, T.
Loupakis, F.
Kawakami, H.
Yamaguchi, K.
Nishina, T.
Fakih, M.
Elez, E.
Rodriguez, J.
Ciardiello, F.
Saxena, K.
Yamamoto, E.
Kobayashi, K.
Bako, E.
Okuda, Y.
Grothey, A.
ANNALS OF ONCOLOGY, 2020, 31 : S1275 - S1275
[33] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic nonesmall cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02
Li, B. T.
Planchard, D.
Goto, K.
Smit, E. F.
De langen, J.
Goto, Y.
Ninomiya, K.
Kubo, T.
Perol, M.
Felip, E.
Hayashi, H.
Nakagawa, K.
Shimizu, J.
Nagasaka, M.
Pereira, K. M. C.
Taguchi, A.
Ali, A.
Karnoub, M.
Yonemochi, R.
Janne, P. A.
ANNALS OF ONCOLOGY, 2023, 34
[34] A PHASE 1/2 STUDY OF SBT6050 COMBINED WITH TRASTUZUMAB DERUXTECAN (T-DXD) OR TRASTUZUMAB AND TUCATINIB WITH OR WITHOUT CAPECITABINE IN PATIENTS WITH HER2-EXPRESSING OR HER2-AMPLIFIED CANCERS
Klempner, Samuel
Strickler, John
Gourley, Lindsey
Jacquemont, Celine
Bhatia, Vinona
Hunder, Naomi
Odegard, Valerie
Piha-Paul, Sarina
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A426 - A426
[35] Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03
Hamilton, Erika P.
Hurvitz, Sara A.
Im, Seock-Ah
Iwata, Hiroji
Curigliano, Giuseppe
Kim, Sung-Bae
Chiu, Joanne Wing-Yan
Pedrini, Jose Luiz
Li, Wei
Yonemori, Kan
Bianchini, Giampaolo
Loi, Sherene
Borges, Giuliano Santos
Wang, Xian
Bachelot, Thomas
Nakatani, Shunsuke
Ashfaque, Shahid
Liang, Zhengkang
Egorov, Anton
Cortes, Javier
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[36] Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
Takayuki Yoshino
Maria Di Bartolomeo
Kanwal Raghav
Toshiki Masuishi
Fotios Loupakis
Hisato Kawakami
Kensei Yamaguchi
Tomohiro Nishina
Zev Wainberg
Elena Elez
Javier Rodriguez
Marwan Fakih
Fortunato Ciardiello
Kapil Saxena
Kojiro Kobayashi
Emarjola Bako
Yasuyuki Okuda
Gerold Meinhardt
Axel Grothey
Salvatore Siena
Nature Communications, 14
[37] Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
Yoshino, Takayuki
Di Bartolomeo, Maria
Raghav, Kanwal
Masuishi, Toshiki
Loupakis, Fotios
Kawakami, Hisato
Yamaguchi, Kensei
Nishina, Tomohiro
Wainberg, Zev
Elez, Elena
Rodriguez, Javier
Fakih, Marwan
Ciardiello, Fortunato
Saxena, Kapil
Kobayashi, Kojiro
Bako, Emarjola
Okuda, Yasuyuki
Meinhardt, Gerold
Grothey, Axel
Siena, Salvatore
NATURE COMMUNICATIONS, 2023, 14 (01)
[38] Updated analysis of DESTINY-Gastric02: A phase II singlearm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/ metastatic gastric/gastroesophageal junction (GEJ) cancer who progressed on or after trastuzumab-containing regimen
Ku, G. Y.
Di Bartolomeo, M.
Smyth, E.
Chau, I.
Park, H.
Siena, S.
Lonardi, S.
Wainberg, Z. A.
Ajani, J. A.
Chao, J.
Barlaskar, F.
Kawaguchi, Y.
Qin, A.
Singh, J.
Meinhardt, G.
Van Cutsem, E.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1100 - S1100
[39] Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2 positive metastatic breast cancer
Modi, Shanu
Saura, Cristina
Yamashita, Toshinari
Park, Yeon Hee
Kim, Sung-Bae
Tamura, Kenji
Andre, Fabrice
Iwata, Hiroji
Ito, Yoshinori
Tsurutani, Junji
Sohn, Joohyuk
Denduluri, Neelima
Perrin, Christophe
Aogi, Kenjiro
Tokunaga, Eriko
Im, Seock-Ah
Lee, Keun Seok
Hurvitz, Sara A.
Cortes, Javier
Lee, Caleb
Liu, Yali
Zhang, Lin
Shahidi, Javad
Yver, Antoine
Baselga, Jose
Krop, Ian E.
CANCER RESEARCH, 2021, 81 (04)
[40] Impact of Serum HER2 Extracellular Domain in Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan (T-DXd)
Nozawa, Kazuki
Kusudo, Maho
Kureyama, Nari
Nakakami, Akira
Komaki, Rie
Endo, Yuka
Kataoka, Ayumi
Kotani, Haruru
Yoshimura, Akiyo
Hattori, Masaya
Sawaki, Masataka
Iwata, Hiroji
CANCER RESEARCH, 2024, 84 (09)

← 1 2 3 4 5 →